Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8626918 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPTCD44KDM4EMEN1 | |
| SCHEMBL30197891 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPTCD44KDM4EMEN1 | |
| SCHEMBL16991796 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPTCD44KDM4EMEN1 | |
| SCHEMBL29522160 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPTCD44KDM4EMEN1 | |
| SCHEMBL2779868 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPTCD44KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL17216600 | 0.98 | ALDH1A1 (0.40) | ALDH1A1MAPTCD44KDM4EMEN1 | |
| Bromide SCHEMBL17217542 | 0.98 | ALDH1A1 (0.40) | ALDH1A1MAPTCD44KDM4EMEN1 | |
| Sulfuric Acid SCHEMBL25199808 | 0.88 | ALDH1A1 (0.43) | ALDH1A1MAPT | |
| Cadaverine Tartrate SCHEMBL16774507 | 0.85 | ALDH1A1 (0.39) | ALDH1A1MAPTKDM4ELMNA | |
| Cadaverine Tartrate SCHEMBL25220108 | 0.85 | ALDH1A1 (0.39) | ALDH1A1MAPTKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4112602-B1 | ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES IN PRESENCE OF A CHIRAL IRIDIUM CATALYST | BAYER AG (DE) | 2026-02-18 | — | — | EP | disclosed |
| US-20260015326-A1 | ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES IN PRESENCE OF A CHIRAL IRIDIUM CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 2026-01-15 | — | — | US | disclosed |
| US-12410138-B2 | Process comprising the use of new iridium catalysts for enantioselective hydrogenation of 4-substituted 1,2-dihydroquinolines | BAYER AKTIENGESELLSCHAFT (DE) | 2025-09-09 | — | — | US | disclosed |
| EP-3774735-B1 | ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES IN PRESENCE OF A CHIRAL IRIDIUM CATALYST | BAYER AG (DE) | 2023-09-13 | — | — | EP | disclosed |
| CN-115836041-A | Process for producing optically active compound | 住友化学株式会社 | 2023-03-21 | — | — | CN | disclosed |
| EP-4112602-A1 | ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES IN PRESENCE OF A CHIRAL IRIDIUM CATALYST | Bayer Aktiengesellschaft (DE) | 2023-01-04 | — | — | EP | disclosed |
| US-20220324810-A1 | PROCESS COMPRISING THE USE OF NEW IRIDIUM CATALYSTS FOR ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-13 | — | — | US | disclosed |
| US-20220306583-A1 | IMPROVED ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES IN PRESENCE OF A CHIRAL IRIDIUM CATALYST AND AN ADDITIVE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-29 | — | — | US | disclosed |
| EP-4034527-A1 | IMPROVED ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES IN PRESENCE OF A CHIRAL IRIDIUM CATALYST AND AN ADDITIVE | Bayer Aktiengesellschaft (DE) | 2022-08-03 | — | — | EP | disclosed |
| CN-114514223-A | Process comprising enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines using a novel iridium catalyst | 拜耳公司 | 2022-05-17 | — | — | CN | disclosed |
| CN-114423739-A | Improved enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts and additives | 拜耳公司 | 2022-04-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324810-A1 | PROCESS COMPRISING THE USE OF NEW IRIDIUM CATALYSTS FOR ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES | IDH3B, HVCN1, HDHD5 | ALDH1A1 368/4885MAPT 4179/4885CD44 3318/4885 |
| US-20260015326-A1 | ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES IN PRESENCE OF A CHIRAL IRIDIUM CATALYST | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-4, H1-0 | ALDH1A1 632/4885MAPT 4821/4885CD44 4555/4885 |
| US-20220306583-A1 | IMPROVED ENANTIOSELECTIVE HYDROGENATION OF 4-SUBSTITUTED 1,2-DIHYDROQUINOLINES IN PRESENCE OF A CHIRAL IRIDIUM CATALYST AND AN ADDITIVE | HRH4, H1-4, IDH3B | ALDH1A1 422/4885MAPT 3708/4885CD44 4007/4885 |
| US-12410138-B2 | Process comprising the use of new iridium catalysts for enantioselective hydrogenation of 4-substituted 1,2-dihydroquinolines | HVCN1, HDHD5, HRH4 | ALDH1A1 469/4885MAPT 3904/4885CD44 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.